Literature DB >> 11829720

Antimicrobial peptides: therapeutic potential for the treatment of Candida infections.

Antonella Lupetti1, Romano Danesi, Jan W van 't Wout, Jaap T van Dissel, Sonia Senesi, Peter H Nibbering.   

Abstract

The increasing frequency of fungal infections in immunocompromised patients together with the emergence of strains resistant to currently used antifungal drugs point to an increased need for a new class of antimycotics. Antimicrobial peptides are promising candidates for the treatment of fungal infections since they have both mechanisms of action distinct from available antifungal agents and the ability to regulate the host immune defence systems as well. This review focuses on Candida albicans as a large amount of work on the mechanisms of action of classical antifungals as well as antimicrobial peptides, such as defensins, protegrins, histatins and lactoferrin (LF)-derived peptides, has been performed in this yeast. Analogues of these antimicrobial peptides and combinations of antimicrobial peptides with classical antimycotics are under investigation for treatment of candidiasis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11829720     DOI: 10.1517/13543784.11.2.309

Source DB:  PubMed          Journal:  Expert Opin Investig Drugs        ISSN: 1354-3784            Impact factor:   6.206


  16 in total

1.  Antifungal activities of human beta-defensins HBD-1 to HBD-3 and their C-terminal analogs Phd1 to Phd3.

Authors:  Viswanatha Krishnakumari; Nandini Rangaraj; Ramakrishnan Nagaraj
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

2.  Synthetic histidine-rich peptides inhibit Candida species and other fungi in vitro: role of endocytosis and treatment implications.

Authors:  Jingsong Zhu; Paul W Luther; Qixin Leng; A James Mixson
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

3.  Candida albicans Cek1 mitogen-activated protein kinase signaling enhances fungicidal activity of salivary histatin 5.

Authors:  Rui Li; Sumant Puri; Swetha Tati; Paul J Cullen; Mira Edgerton
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

Review 4.  Multifunctional antimicrobial peptides: therapeutic targets in several human diseases.

Authors:  Mohamed Zaiou
Journal:  J Mol Med (Berl)       Date:  2007-01-10       Impact factor: 4.599

5.  Structural Characterization of Histatin 5-Spermidine Conjugates: A Combined Experimental and Theoretical Study.

Authors:  Stephanie Jephthah; João Henriques; Carolina Cragnell; Sumant Puri; Mira Edgerton; Marie Skepö
Journal:  J Chem Inf Model       Date:  2017-06-06       Impact factor: 4.956

6.  Regulation of fungal infection by a combination of amphotericin B and peptide 2, a lactoferrin peptide that activates neutrophils.

Authors:  Tetsuro Okamoto; Toyohiro Tanida; Benjuan Wei; Eisaku Ueta; Tetsuya Yamamoto; Tokio Osaki
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

7.  Different anti-Candida activities of two human lactoferrin-derived peptides, Lfpep and kaliocin-1.

Authors:  Mónica Viejo-Díaz; María T Andrés; José F Fierro
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

8.  Normal human gingival epithelial cells sense C. parapsilosis by toll-like receptors and module its pathogenesis through antimicrobial peptides and proinflammatory cytokines.

Authors:  Raouf Bahri; Sèverine Curt; Dalila Saidane-Mosbahi; Mahmoud Rouabhia
Journal:  Mediators Inflamm       Date:  2010-05-03       Impact factor: 4.711

9.  Human salivary MUC7 mucin peptides: effect of size, charge and cysteine residues on antifungal activity.

Authors:  Hongsa Situ; Guoxian Wei; Christina J Smith; Shirin Mashhoon; Libuse A Bobek
Journal:  Biochem J       Date:  2003-10-01       Impact factor: 3.857

10.  Salivary secretory leukocyte protease inhibitor and oral candidiasis in human immunodeficiency virus type 1-infected persons.

Authors:  Amit Chattopadhyay; Laurie R Gray; Lauren L Patton; Daniel J Caplan; Gary D Slade; Hsaio-Chuan Tien; Diane C Shugars
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.